# A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy Adults

> **NCT05624580** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 56 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** NNC0582-0001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05624580
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-15
- **Primary completion:** 2025-10-16
- **Final completion:** 2025-10-16
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624580, "A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05624580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*